Lanreotide Zentiva (Lanreotide)

Lanreotide mimics natural somatostatin and binds to somatostatin receptors on endocrine and tumor cells. This binding blocks adenylate cyclase, reduces calcium influx, and suppresses the release of growth hormone, insulin‑like growth factor‑1 and other peptide hormones.

The dosage and administration schedule are determined by the prescribing clinician based on the patient’s condition, response and tolerability. Lanreotide is typically given as a subcutaneous injection at intervals recommended by the healthcare professional.

Safety data for Lanreotide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Lanreotide Zentiva product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

The primary alternative is octreotide, another somatostatin analogue. Both agents suppress hormone secretion, but Lanreotide has a longer dosing interval, allowing less frequent injections, whereas octreotide often requires more frequent dosing. Choice depends on clinical response, patient preference and physician judgment.

Lanreotide must be stored refrigerated at 2‑8 °C. Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If temporary storage at room temperature is unavoidable, limit exposure to less than 24 hours.

Lanreotide is given by subcutaneous injection, usually into the abdomen or thigh. The injection is performed by a healthcare professional or, after proper training, by the patient or caregiver according to the prescribed schedule.

Serious adverse events include gallstone formation, pancreatitis, severe hypersensitivity reactions such as anaphylaxis, and marked hyperglycaemia that may require medical intervention. Patients should be monitored for these conditions throughout therapy.

Lanreotide is contraindicated in patients with known hypersensitivity to lanreotide or any of its excipients. Caution is advised for individuals with uncontrolled diabetes, severe hepatic or renal impairment, and active gallbladder disease, as these conditions may increase the risk of complications.